Skip to content
Skip to search
Skip to footer
- ALIGN AR-A Study to Assess Safety and Effectiveness of the JenaValve Trilogy™ Heart Valve System in the Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation (AR). Alan Zajarias, MD. Jenavalve.
CURRENTLY ENROLLING
- Alliance- Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve. Marc Sintek, MD. Edwards Lifesciences.
IN FOLLOW-UP
- Alliance AVIV- Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves. Marc Sintek, MD. Edwards Lifesciences.
CURRENTLY ENROLLING
- Alta Valve- AltaValve™ Pivotal Trial Protocol. Alan Zajarias, MD. 4C Medical Technologies, Inc.
CURRENTLY ENROLLING
- APOLLO-Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR System in patients with severe symptomatic mitral regurgitation. Alan Zajarias, MD. Medtronic, Inc.
CURRENTLY ENROLLING
- CLASP II- Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP II TR): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation. Alan Zajarias, MD. Edwards Lifesciences.
CURRENTLY ENROLLING
- CLASP IIF- Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with mitral regurgitation. Alan Zajarias, MD. Edwards Lifesciences.
CURRENTLY ENROLLING
- EmBlok- A Prospective, Randomized, Multicenter Evaluation of the Safety and Effectiveness of the EMBLOK™ Embolic Protection System during Transcatheter Aortic Valve Replacement. Alan Zajarias, MD. Innovative Cardiovascular Solutions, LLC.
CURRENTLY ENROLLING
- EXCEED- A Prospective, Single-arm, Controlled, Multicenter Study to Establish the Safety and Effectiveness of the CENTERA THV System in IntermEDiate Risk Patients who have Symptomatic, Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement (ExCEED). Alan Zajarias, MD. Edwards Lifesciences.
IN FOLLOW-UP
- JENA-VAD- Transcatheter Aortic Valve Replacement using the JenaValve TrilogyTM Heart Valve System for Clinically Significant Aortic Regurgitation in Patients with Left Ventricular Assist Devices (LVAD). Alan Zajarias, MD. Jenavalve.
CURRENTLY ENROLLING
- Journey-AR- J-Valve to Treat Aortic Regurgitation via Transcatheter Therapy. Alan Zajarias, MD. JC Medical.
CURRENTLY ENROLLING
- PARTNER 3- A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients who have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement. Alan Zajarias, MD. Edwards Lifesciences
IN FOLLOW-UP
- PARTNER 3 MVIV- A Prospective, Single-Arm, Multicenter Study to Investigate the Safety and Effectiveness of SAPIEN 3 Transcatheter Heart Valve Implantation in Patients With a Failing Mitral Bioprosthetic Valve. Alan Zajarias, MD. Edwards Lifesciences.
IN FOLLOW-UP
- PARTNER 3 AVIV- A Prospective, Single-Arm, Multicenter Study to Investigate the Safety and Effectiveness of SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve Implantation in Patients With a Failing Aortic Bioprosthetic Valve-PARTNER 3 Trial. Alan Zajarias, MD. Edwards Lifesciences.
IN FOLLOW-UP
- ProTembo Cerebral Protection in Transcatheter Aortic Valve Replacement. Alan Zajarias, MD. Protembis.
CURRENTLY ENROLLING
- TRICAV-I- A prospective, multicenter clinical trial of the TricValve® Transcatheter Bicaval Valve System in subjects with severe tricuspid regurgitation. Alan Zajarias, MD. P + F USA Inc.
CURRENTLY ENROLLING